14305-08-9

Usage

Uses

4,5-Dibromo-2-phenylpyridazin-3(2H)-one (cas# 14305-08-9) is a useful research chemical.

InChI:InChI=1/C10H6Br2N2O/c11-8-6-13-14(10(15)9(8)12)7-4-2-1-3-5-7/h1-6H

Upstream product

• 488-11-9 mucobromic acid 
• 100-63-0 phenylhydrazine 
• 21577-50-4 mucobromic acid 
• 766-38-1 mucobromic acid 
• 62-53-3 aniline 

Downstream Products

• 21456-76-8 4-bromo-2-phenyl-5-piperidino-2H-pyridazin-3-one 
• 10002-74-1 4-bromo-5-ethoxy-2-phenyl-2H-pyridazin-3-one 
• 21456-72-4 4-bromo-5-methylamino-2-phenyl-2H-pyridazin-3-one 
• 38321-78-7 4-bromo-5-hydroxy-2-phenyl-2H-pyridazin-3-one 
• 128457-11-4 4-Bromo-5-(N-methyl-hydrazino)-2-phenyl-2H-pyridazin-3-one 
• 67397-23-3 5-ethoxy-2-phenyl-2H-pyridazin-3-one 
• 1549706-16-2 4-bromo-2-phenyl-5-(((tetrahydrofuran-2-yl)methyl)amino)pyridazin-3(2H)-one 
• 1549706-05-9 2-((5-bromo-6-oxo-1-phenyl-1,6-dihydropyridazin-4-yl)amino)acetamide 
• 1549705-88-5 2-(5-bromo-6-oxo-1-phenyl-1,6-dihydropyridazin-4-yl)-1,2,3,4-tetrahydroisoquinoline-5-carbonitrile 
• 28081-44-9 5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-4-bromo-2-phenylpyridazin-3(2H)-one 
• 1549709-41-2 5-azido-4-isopropyl-2-phenylpyridazin-3(2H)-one 
• 1549706-46-8 5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-4-isopropyl-2-phenylpyridazin-3(2H)-one 
• 1549705-95-4 4-bromo-2-phenyl-5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridazin-3(2H)-one 
• 1549708-99-7 2-phenyl-4-isopropyl-5-bromopyridazin-3(2H)-one 

Relevant academic research and scientific papers

Discovery of 5-substituted-N-arylpyridazinones as inhibitors of p38 MAP kinase

The synthesis, structure-activity relationship and modeling of a series of 5-substituted-N-aryl pyridazinone based p38α inhibitors are described. In comparing the series to the similar N-aryl pyridinone series, it was found that the pyridazinones maintain

Confirmation and prevention of halogen exchange: practical and highly efficient one-pot synthesis of dibromo- and dichloropyridazinones

Commercially available anilines were converted by a two step, one-pot process to the corresponding pyridazinones in good to excellent yields. During the process research, a significant halogen exchange was confirmed and prevented which allowed the process to be scaled to multikilogram quantities.

Substituted pyridazinones

Disclosed are substituted pyridazinones that are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical composition containing the pyridazinone compounds, methods of preparing th